Serum Chemerin as a Marker for Early Detection of Metabolic Syndrome in Obese Children

Document Type : Original Article

Authors

1 Department of Pediatrics, El Ibrahimiya central hospital, Sharqia, Egypt

2 Department of Pediatrics, Faculty of Medicine, Suez Canal University, Egypt

Abstract

Background: Chronic inflammatory conditions include metabolic syndrome (MetS), one of the most important worldwide health concerns. Chemerin, an adipokine, is involved in the relationship between MetS and inflammation. Aim: The goal of our research was to assess if serum chemerin might be used as a marker for early diagnosis of metabolic syndrome. Methods: The study included 42 obese and 42 non-obese healthy children and adolescents ranging in age from 5 to 17 years old. The subjects' anthropometric and blood pressure measurements were taken. The following data were collected: fasting blood glucose, serum triglycerides (TG), total cholesterol, high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c). The level of chemerin was measured using ELISA. Results: Serum chemerin levels were substantially greater in MetS obese than in non-MetS obese and healthy subjects (1211.71569 ng/ml versus 337.534.8 ng/ml and 470.3475.8 ng/ml, respectively, p0.001). By using correlation and multiple linear regression analysis, serum chemerin levels were found to be significantly correlated to impaired fasting blood sugar (r= 0.398, p = 0.009) and poor HDL (r= -0.386, p = 0.012). Conclusion: Chemerin levels in the blood have been linked to metabolic syndrome and could be used as an independent diagnostic marker for the condition.
 

Keywords

Main Subjects

Files

Share

How to cite

Statistics